ILLUMINATE
21 Dec 2020
Trial Summary
The primary purpose of this trial is to evaluate the efficacy and tolerability of durvalumab and tremelimumab with platinum-pemetrexed in patients with metastatic NSCLC (T790+ve or T790M-ve) following progression on EGFR Tyrosine Kinase Inhibitors.
Acronym:
ILLUMINATE
ACTRN/NCT /ethics:
NCT03994393
Scientific title:
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
Sponsor / Cooperative group:
University of Sydney
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2018-10-23 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Shawgi Sukumaran |
| Recruitment Status | Recruiting |